Endocrine Abstracts

Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...

Purpose: IGF-1R antagonism reduces TED-related inflammation and proptosis. VRDN-001, a subnanomolar affinity full antagonist antibody to IGF-1R, is being evaluated in a phase 1/2 RCT (NCT05176639) at 3-20 mg/kg. We present results from the first cohort (10 mg/kg) of TED patients.Methods: Adults with active moderate-to-severe TED with clinical activity score (CAS) ≥4 were randomized to 2 infusions 3 weeks apart of either 10 mg/kg VRDN-001 or placebo...

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

Objectives: The insulin-like growth factor I receptor (IGF-1R) plays a significant role in the pathology of thyroid eye disease (TED), an autoimmune disorder characterized by orbital inflammation. Teprotumumab, a human monoclonal antibody targeting IGF-1R, has demonstrated efficacy in treating moderate-to-severe TED. A significant proportion of patients experienced adverse events (AEs), with 74% and 85% reporting an AE and 12% and 5% reporting serious AEs in Phase 2 and 3 tria...